ClinicalTrials.gg
RecruitingNCT05778617ASPro-PDUpdated May 1, 2025

Ambroxol to Slow Progression in Parkinson Disease

A Phase 3 interventional study of Ambroxol Hydrochloride (420mg) and Placebo in Parkinson Disease, sponsored by University College, London. Recruiting at 15 sites in United Kingdom. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by University College, London · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Parkinson Disease by University College, London — 4 open to participants now, 4 under way, 2 of them phase 3. Parkinson Disease · University College, London.

Planned enrollment
2nd of 12
330 · median 56
Started
2025
with 1 other
Phase 3
4 of 16
2 open now
Registered
14th of 16
by date

Among the 16 studies in Parkinson Disease by University College, London, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 3, and was the 14th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

4 of the 16 studies in Parkinson Disease by University College, London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Parkinson Disease by University College, London, or all of them as a file.
02

Study summary

This is a UK only clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol hydrochloride, which is an already licensed drug for the treatment of respiratory conditions (such as a common cold) in many European countries. The aim of this trial is to find out whether ambroxol hydrochloride can slow down the progression of Parkinson's disease and to evaluate it's safety and tolerability.

Read the detailed description

This is a 104-week, randomized, double-blind, multi-centre, parallel group, placebo-controlled clinical trial of ambroxol hydrochloride in patients with PD, with a 26-week open-label extension phase. Participants will undergo screening to evaluate their eligibility to participate in the trial. All eligible participants will be randomised to receive either ambroxol hydrochloride (420mg) or it's matching placebo in a 1:1 ratio three times a day for 104 weeks, including a 2-week dose escalation period. Once the end of the blinded treatment has been reached, all participants will enter the open-label extension phase and will receive ambroxol hydrochloride (420mg) three times a day for 26 weeks, including a 2-week dose escalation period. All clinical staff, study investigators, and participants will be blinded to study assignments throughout the entirety of the trial.

There will be an optional sub-study including 106 participants in which a cerebrospinal fluid (CSF) sample will be taken on two occasions via a Lumbar Puncture procedure to measure ambroxol drug levels, assess whether the glucocerebrosidase enzyme has been stimulated and the levels of other substances thought to be associated with the development of PD and confirm whether the study drug has penetrated the cerebrospinal fluid and Central Nervous System.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Parkinsonian Disorders
  • Basal Ganglia Diseases
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Movement Disorders
  • Neurodegenerative Diseases
  • Ambroxol
  • Synucleinopathies
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of Parkinson's disease (in accordance with the MDS diagnostic criteria) within 7 years of the screening visit confirmed by year of diagnosis.
  2. Adults aged ≥ 35 and ≤ 75 years.
  3. Hoehn and Yahr stage between 1-2.5, inclusive (in ON stage) at screening visit.
  4. Known glucocerebrosidase gene (GBA1) status, positive or negative (status MUST be confirmed prior to screening).
  5. On stable dopaminergic treatment for at least 3 months before enrolment.
  6. Able and willing to provide prior to any study related assessments and/or procedures.
  7. Able and willing to attend trial visits and comply with all study procedures for the duration of the trial.
  8. Willing and able to self-administer oral ambroxol medication or placebo.

Exclusion criteria

Exclusion Criteria:

  1. Participation in another interventional clinical trial of an Medicinal Product (IMP) and use of an Investigational Medicinal Product (IMP) within 90 days prior to the first dose of trial treatment.
  2. Use of an Investigational Medicinal Product (IMP) within 90 days prior to the first dose of trial treatment.
  3. Participation in another clinical trial of an Investigational New Drug being tested for PD disease modifying potential within 12 months prior to the first dose of trial treatment.
  4. Past surgical history of deep brain stimulation.
  5. Use of ambroxol in the past 12 months.
  6. Exposure to Exenatide within 12 months prior to the first dose in this current trial.
  7. Concomitant medications that in the opinion of the Investigator would preclude participation in the study e.g., exenatide or other GLP1 agonist for diabetes.
  8. Confirmed dysphagia that would preclude self-administration of ambroxol.
  9. History of known sensitivity to the study medication, ambroxol or its (lactose monohydrate, granulated microcrystalline cellulose, copovidone and magnesium stearate) in the opinion of the investigator that contraindicates their participation.
  10. History of known rare hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
  11. Presence of the LRRK2 G2019S mutation (status to be confirmed prior to screening).
  12. History of drug abuse or alcoholism in the opinion of the Investigator that would preclude participation in the trial.
  13. Pregnant (or planned pregnancy during the trial) and/or breastfeeding.
  14. Women of (WOCBP) and male participants with a partner of childbearing potential not willing to use highly effective or abstinence for the duration of the trial treatment and for 2 weeks following the last dose of the study drug.
  15. Any or unstable medical or surgical condition that in the opinion of the Investigator may; put the participant at risk when participating in the study, influence the results of the study or affect the participants ability to take part in the study, as determined by medical history, physical examinations, (ECG) or laboratory tests. Such conditions may include:

    A. Impaired renal function with \<50ml/min at screening visit.

    B. Moderate/Severe hepatic impairment.

    C. A major cardiovascular event (e.g., myocardial infarction, acute coronary syndrome, compensated congestive heart failure, pulmonary embolism, coronary revascularisation) that occurred within 6 months prior to the screening visit.

  16. Severe depression defined by a score >20 on the Beck Depression Inventory-II (BDI-II) at screening.
  17. Significant cognitive impairment defined by a score \<20 on the (MoCA) at screening.
  18. Use of trihexyphenidyl or benztropine within 30 days prior to the first dose of trial treatment.
  19. Only applicable for those patients consenting to the optional CSF sub-study: Evidence or history of to lidocaine or its derivatives.
  20. Only applicable for those patients consenting to the optional CSF sub-study: current treatment with anti-coagulants (e.g., warfarin) that might preclude safe completion of the lumbar puncture in the opinion of the Investigator. Aspirin will be permitted.
  21. Only applicable for those patients consenting to the optional CSF sub-study: Significant known lower spinal malformations or other spinal abnormalities that would preclude a lumbar puncture.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
330 participants (estimated)

Study arms

  • Active comparator
    Ambroxol hydrochloride

    Participants will receive ambroxol hydrochloride (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase. n=165

    Drug: Ambroxol Hydrochloride (420mg)

  • Placebo comparator
    Placebo

    Participants will receive ambroxol hydrochloride matching placebo (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride matching placebo 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase. n=165

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I- III score from baseline to Week 104.

    The MDS-UPDRS is a comprehensive 50 question assessment of both motor and non-motor symptoms associated with Parkinson's. Comparison of MDS-UPDRS Parts I-III total score at 104 weeks between participants according to treatment allocation will be made. Parts I and II are measured in the practically defined ON medication state and Part III is measured in the practically defined OFF medication state. Parts I and II are historical data assessed by an examiner and are designed to rate mentation, behaviour and mood; Part III is done as a motor examination at the time of a visit. Participants will undergo MDS-UPDRS assessment at baseline, week 20, week 40, week 60, week 80, week 104. The MDS-UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario. MDS-UPDRS score = sum of Parts I, II and III (Range: 0 to 236). Higher score indicative of worse outcome.

    Time frame: Baseline; Week 104

Secondary outcomes

  1. Motor signs of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score in the OFF medication state from baseline to Week 104.

    This component of the MDS-UPDRS scale (Section III) assesses the motor signs of PD and will involve a motor examination at the time of a visit. The score ranges from 0 to 132. Higher score is indicative of worse outcome.

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

  2. Motor complications of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV score in the ON medication state from baseline to Week 104.

    This component of the MDS-UPDRS scale (Section IV) assesses two motor complications, dyskinesias and motor fluctuations using historical and objective information. The score ranges from 0 to 24. Higher score indicative of worse outcome.

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

  3. The non-motor impact of PD on patients using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part I score in the ON medication state baseline to Week 104.

    This component of the MDS-UPDRS scale (Section I) assesses the non-motor impact of Parkinson's disease (PD) on patients' experiences of daily living. The score ranges from 0 to 24. Higher score indicative of worse outcome.

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

  4. The motor aspect impact of PD of patients experiences on daily living using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II score in the ON medication state from baseline to Week 104.

    This component of the MDS-UPDRS scale (Section II) assesses the motor aspect impact of Parkinson's disease (PD) on patients' experiences of daily living. The score ranges from 0 to 52. Higher score indicative of worse outcome.

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

  5. The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) tremor score from baseline to Week 104.

    The tremor components of the MDS-UPDRS scale

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

  6. The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) non-tremor score from baseline to Week 104.

    The non-tremor components of the MDS-UPDRS scale

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

  7. Cognitive impairment using the Montreal Cognitive Assessment from baseline to Week 104.

    A 30 question test which assesses mild cognitive impairment by checking participant orientation, short-term memory, executive function, language, abstraction, naming of animals, attention and a clock drawing test. Maximum score= 30. Lower scores indicative of worse outcome.

    Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  8. Patient reported measure of health status and quality of life using the Parkinson's disease 39 item Quality of Life questionnaire from baseline to Week 104.

    A questionnaire which assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living. The 39 item questionnaire offers a patient reported measure of health status and quality of life and is the most frequently used disease-specific health status measure. Maximum score = 156. Higher score= worse outcome.

    Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  9. Symptom improvement from baseline to Week 104 using the Patient Global Impression of Change from baseline to Week 104.

    A 1 item questionnaire which asks a participant to report their own impression of change in their clinical status. Maximum score = 7. Higher score= worse outcome.

    Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  10. Quality-of-Life outcome differences between the two treatment groups from baseline to Week 104, as measured by the descriptive system for health-related quality of life, EQ-5D-5L.

    The EQ-5D-5L is a participant self-reported questionnaire which evaluates the generic quality of life at the time of completion. It comprises of one question for each of the five dimensions ;no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. An Visual Analogue Scale is also used and is a scale measured from 0 -100 scale where patients are asked to indicate their overall health on the day of questionnaire completion. Maximum score = 100. Lower score = worse outcome.

    Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  11. Non-motor symptoms of PD from baseline to Week 104 , as measured by the Non-Motor Symptoms Scale.

    The Non-Motor Symptoms Scale (NMSS) is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. Maximum score = 360. Higher score = worse outcome.

    Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  12. PD progression measured using Parkinson's Disease Comprehensive Response from baseline to Week 104

    A composite approach integrating three standard outcome measures PDCORE = (1 × change in OFF state motor score) + (2 × change in OFF state ADL score) - (10 × change in total good-quality ON time per day). Higher score = worse outcome.

    Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  13. Assessment of postural instability and falls from baseline to Week 104 using the Dresden Falls Questionnaire.

    A self-reported assessment of falls, near falls, fear of falling, fall-related injuries, and causes of falls for patients with Parkinson's disease. Maximum score = 12. Higher score = worse outcome.

    Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  14. Symptom severity, treatment response and the efficacy of treatment from baseline to Week 104 using the Clinical Global Impression of symptom severity and improvement scales.

    Research team assessment. The CGI has two components-the CGI-Severity, which rates illness severity, and the CGI-Improvement, which rates change from the initiation (baseline) of treatment. Maximum score = 14. Higher score = worse outcome.

    Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  15. Safety and tolerability of ambroxol hydrochloride as indicated by changes in pulse (bpm) from baseline to Week 104

    Vital signs

    Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  16. Safety and tolerability of ambroxol hydrochloride as indicated by changes in blood pressure (mmHg) from baseline to Week 104

    Vital signs

    Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  17. Safety and tolerability of ambroxol hydrochloride as indicated by changes in temperature (°) from baseline to Week 104

    Vital signs

    Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  18. Safety and tolerability of ambroxol hydrochloride as indicated by changes in respiratory rate (breaths per minute)from baseline to Week 104

    Vital signs

    Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  19. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Body Mass Index (weight and height will be combined to report BMI in kg/m^2) from baseline to Week 104

    Vital signs

    Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  20. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Red Blood Cell Count (10^12/L) from baseline to Week 104

    Standard diagnostic laboratory test (Full Blood Count)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  21. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Haemoglobin (g/dL) from baseline to Week 104

    Standard diagnostic laboratory test (Full Blood Count)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  22. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Haematocrit (%) from baseline to Week 104

    Standard diagnostic laboratory test (Full Blood Count)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  23. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Platelets (10^9/L) from baseline to Week 104

    Standard diagnostic laboratory test (Full Blood Count)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  24. Safety and tolerability of ambroxol hydrochloride as indicated by changes in White Blood Cell Count (10^9/L) from baseline to Week 104

    Standard diagnostic laboratory test (Full Blood Count)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  25. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Neutrophils (10^9/L) from baseline to Week 104

    Standard diagnostic laboratory test (Full Blood Count)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  26. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Eosinophils (10^9/L) from baseline to Week 104

    Standard diagnostic laboratory test (Full Blood Count)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  27. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Basophils (10^9/L) from baseline to Week 104

    Standard diagnostic laboratory test (Full Blood Count)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  28. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Lymphocytes (10^9/L) from baseline to Week 104

    Standard diagnostic laboratory test (Full Blood Count)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  29. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Monocytes (10^9/L) from baseline to Week 104

    Standard diagnostic laboratory test (Full Blood Count)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  30. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Urea (mmol/L) from baseline to Week 104

    Standard diagnostic laboratory test (Biochemistry)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  31. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Sodium (mmol/L) from baseline to Week 104

    Standard diagnostic laboratory test (Biochemistry)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  32. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Potassium (mmol/L) from baseline to Week 104

    Standard diagnostic laboratory test (Biochemistry)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  33. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Creatinine (µmol/L) from baseline to Week 104

    Standard diagnostic laboratory test (Biochemistry)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  34. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Total Bilirubin (µmol/L)from baseline to Week 104

    Standard diagnostic laboratory test (Biochemistry)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  35. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Alkaline phosphatase (IU/L) from baseline to Week 104

    Standard diagnostic laboratory test (Biochemistry)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  36. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Alanine transaminase (IU/L) from baseline to Week 104

    Standard diagnostic laboratory test (Biochemistry)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  37. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Aspartate Aminotransferase (IU/L) from baseline to Week 104

    Standard diagnostic laboratory test (Biochemistry)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  38. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Uric Acid (mg/dL) from baseline to Week 104

    Standard diagnostic laboratory test (Biochemistry)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  39. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Bicarbonate (mmol/L) from baseline to Week 104

    Standard diagnostic laboratory test (Biochemistry)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  40. Safety and tolerability of ambroxol hydrochloride as indicated by changes in Chloride (mmol/L) from baseline to Week 104

    Standard diagnostic laboratory test (Biochemistry)

    Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104

  41. Safety and tolerability of ambroxol hydrochloride as indicated by the occurrence / severity of treatment related Adverse Events assessed by CTCAE v5.0 from baseline to Week 104

    Number of participants with treatment related adverse events assessed by CTCAE v5.0 from baseline to Week 104.

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  42. Time to initiation of rescue medication

    Length of time until initiation of rescue medication from baseline to Week 104.

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  43. Change in levodopa equivalent dose at 104 weeks

    Calculated levodopa equivalent dose from baseline to Week 104.

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Other outcomes

  1. The association between ambroxol, the glucocerebrosidase enzyme and other proteins associated with the development of PD measured by glucocerebrosidase enzyme activity and other protein markers in blood and cerebrospinal fluid (CSF) samples.

    There is evidence of a reciprocal relationship between PD development and glucocerebrosidase enzyme activity. Testing levels of glucocerebrosidase enzyme activity in blood and CSF samples is used to assess the ability of ambroxol to modulate glucocerebrosidase enzyme activity.

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  2. The association between ambroxol and alpha-synuclein levels in blood and cerebrospinal fluid (CSF) samples from baseline to Week 104.

    Alpha-synuclein is a key protein involved in Parkinson's disease (PD) pathology. Testing levels of Alpha-synuclein in blood and CSF samples is used to access the ability of ambroxol to modulate Alpha-synuclein activity.

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  3. The association between ambroxol and glycerylceramide, neurofilament light chain and lipid levels in cerebrospinal fluid (CSF) samples from baseline to Week 104.

    Testing levels of glycerylceramide, neurofilament light chain and lipid levels in CSF samples is used to access the ability of ambroxol to modulate their activity.

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

  4. Affect of GBA status on all measurement outcomes for both treatment arms from baseline to Week 104.

    Analysis of all outcome data from both treatment arms in comparison to GBA status at screening.

    Time frame: Baseline and Week 104

  5. Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I- IV score from baseline to Week 130.

    The MDS-UPDRS is a comprehensive 50 question assessment of both motor and non-motor symptoms associated with Parkinson's. Participants will undergo MDS-UPDRS assessment at baseline, week 20, week 40, week 60, week 80, week 104 and week 130. The MDS-UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario. MDS-UPDRS score = sum of Parts I, II, III and IV. Higher score indicative of worse outcome.

    Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104; Week 130

  6. Comparison of change in the gut microbiome composition from baseline to Week 104.

    Faecal samples will be collected to analyse the gut microbiome.

    Time frame: Baseline and Week 104.

  7. Comparison of The Smell Identification Test [UPSIT] score change from baseline to week 104.

    Smell identification to test the function of an individual's olfactory system.

    Time frame: Baseline and Week 104.

07

Study locations

3 of 15 sites recruiting
  • University Hospitals Birmingham
    Birmingham, United Kingdom
    Not yet recruiting
    • Ben Wright · Contact
    • Ben Wright, Dr · Principal investigator
  • Southmead Hospital Bristol
    Bristol, United Kingdom
    Not yet recruiting
    • Alan Whone · Contact
    • Alan Whone, Dr · Principal investigator
  • Addenbrookes NHS Trust
    Cambridge, United Kingdom
    Not yet recruiting
    • Caroline Williams-Gray · Contact
    • Caroline Williams-Gray, Dr · Principal investigator
  • Western General Hospital
    Edinburgh, United Kingdom
    Not yet recruiting
    • David Breen · Contact
    • David Breen, Dr · Principal investigator
  • Kings College London
    London, United Kingdom
    Not yet recruiting
    • Ray Chaudhuri · Contact
    • Ray Chaudhuri, Prof. · Principal investigator
  • Royal London Hospital
    London, United Kingdom
    Not yet recruiting
    • Alastair Noyce · Contact
    • Alastair Noyce, Prof. · Principal investigator
  • University College London Hospital's
    London, United Kingdom
    Recruiting
    • Marco Toffoli · Contact
    • Marco Toffoli, Dr · Principal investigator
  • Northumbria
    Newcastle Upon Tyne, United Kingdom
    Not yet recruiting
    • James Fisher · Contact
    • James Fisher, Dr · Principal investigator
  • Newcastle
    Newcastle, United Kingdom
    Not yet recruiting
    • Nicola Pavese · Contact
    • Nicola Pavese, Prof. · Principal investigator
  • The John Radcliffe Hospital
    Oxford, United Kingdom
    Not yet recruiting
    • Michele Hu · Contact
    • Michele Hu, Prof. · Principal investigator
  • Derriford Hospital
    Plymouth, United Kingdom
    Recruiting
    • Stephen Mullin · Contact
    • Stephen Mullin, Dr · Principal investigator
  • Fairfield General Hospital
    Salford, United Kingdom
    Not yet recruiting
    • Robert Irving · Contact
    • Robert Irving, Dr · Principal investigator
  • Salford Royal Hospital
    Salford, United Kingdom
    Recruiting
    • Monty Silverdale · Contact
    • Monty Silverdale, Prof. · Principal investigator
  • Southampton General Hospital
    Southampton, United Kingdom
    Not yet recruiting
    • Boyd Ghosh · Contact
    • Boyd Ghosh, Dr · Principal investigator
  • Prince Philip Hospital
    Wales, United Kingdom
    Not yet recruiting
    • Mark Sheehan · Contact
    • Mark Sheehan, Dr · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2029, 48 months after the start.

Of 68 phase 3 interventional studies under Parkinson Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Mar 21, 2023
StartActual
Feb 25, 2025
Primary completionEst.
Feb 2029
CompletionEst.
Sep 2029
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05778617
Responsible party
Sponsor
First posted
Mar 21, 2023
Start date
Feb 25, 2025
Primary completion
Feb 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
May 1, 2025

Study contacts

ASPro-PD Trial Team
Contact
cctu.aspro-pd@ucl.ac.uk
02031084908
Felicia Ikeji
Contact
f.ikeji@ucl.ac.uk
02076799506
Anthony Schapira
principal investigator · University College, London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ambroxol

Start the discussion